CA
NZ
UK
AU
IND
US
Rayonier Advanced Materials Inc. (NYSE: RYAM) posted second-quarter net sales of $376 million, marking an 18% rise from the first quarter. Year-over-year comparisons reveal an 11% increase in sales, as the company navigates ongoing operational improvements. While this revenue growth is promising, the reported …
RenovoRx, Inc. (NASDAQ: RNXT) aims to highlight its innovative Trans-Arterial Micro-Perfusion (TAMP) platform during an upcoming webinar on August 13. This session, titled "The Evolving Pancreatic Cancer Landscape," will showcase the potential of RenovoCath, the company’s FDA-cleared drug-delivery device, in treating pancreatic cancer. The …
Adjusted earnings per share soared to $1.41, exceeding analysts' consensus estimate of $1.25. This performance reflects Revvity's ability to navigate market conditions effectively, giving investors a positive outlook on its growth trajectory. The reported results indicate Revvity's resilience, especially in light of the evolving …
Rhythm Pharmaceuticals (NASDAQ: RYTM) delivered a quarterly revenue surge, posting $71.3 million from IMCIVREE sales, a 19% jump from the prior quarter, while earnings per share improved to $‑0.73 versus the $‑0.84 consensus. The boost stems from strong U.S. demand and expanding patient uptake, …
Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) announced total revenues of $78.7 million for the second quarter, driven by a 14% year-over-year increase in net product sales to $67.0 million. This performance comes despite reporting earnings per share of $0.44 in the previous quarter, which fell …
Pfizer Inc. (NYSE: PFE) reported solid second-quarter 2026 results, with revenues totaling $15.0 billion, a 3% increase from the prior year. This growth, despite a decline in COVID-19 product revenues, reflects a strong performance mainly from non-COVID products, leading the company to raise its …
Precigen (NASDAQ: PGEN) reported PAPZIMEOS net revenue of $53.1 million for the quarter ended June 30, 2026, more than double the prior quarter and enough to generate a net income of $20.1 million, or $0.05 per share. The company said the rapid uptake of …
This revenue marks a more than twofold increase from the previous quarter, demonstrating the accelerating market adoption of its PAPZIMEOS treatment for recurrent respiratory papillomatosis (RRP). This compelling performance offers a striking contrast to its results from the prior year, where it recorded a …
This surge was driven by a significant uptick in U.S. procedures, which surpassed 13,100, up approximately 21% compared to the same period in 2025. The revenue outcome also matched the consensus estimate for earnings per share (EPS) of $-0.47. With a current market cap …
This purchase strengthens P&G's presence in the fast-growing health and wellness market, which is gaining traction as consumers increasingly shift toward preventive health measures. Management indicated that the acquisition aligns with P&G's strategic focus on expanding its health-related offerings to meet rising demand. The …
Please wait processing your request...